Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Targeted Therapy for Breast Cancer: Focus on the Apoptosis Pathway
share announcement

Targeted Therapy for Breast Cancer: Focus on the Apoptosis Pathway

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 3170

Special Issue Editors

Dr. Jangsoon Lee

E-Mail Website
Guest Editor
Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interests: translational research; aggressive breast cancer; preclinical research; drug-resistance mechanism; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals
Dr. Bora Lim

E-Mail Website
Guest Editor
Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
Interests: metastatic breast cancer; clinical trials; inflammatory breast cancer; triple negative breast cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleague,

Apoptosis is a type of programmed cell death. There are two major types of apoptosis pathway: 1) intrinsic pathways that are initiated by intracellular pathways such as DNA damage, ER stress, hypoxia, and metabolic stress, and 2) extrinsic pathways that are initiated by death receptor activation (TRAILR and FAS) from a signal outside cells. Apoptosis resistance is a hallmark of human cancer, and apoptosis regulators have been targeted for drug development regarding cancer treatment. Breast cancer is a heterogeneous disease that often develops resistance toward standard care treatments, such as hormone therapy, anti-HER2 therapy, chemotherapy, or radiotherapy. It has been reported that anti-apoptotic BCL-2 family members are frequently found to be up-regualated in breast cancer and correlate with poor prognosis. In this issue, we welcome original research and review articles that discuss the discovery of novel mechanisms of apoptosis, potential drug targets, biomarkers, and new inhibitors that may overcome apoptosis resistance and provide effective therapeutic approaches for use in the treatment of breast cancer.

Dr. Jangsoon Lee
Dr. Bora Lim
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • apoptosis
  • intrinsic apoptosis pathways
  • extrinsic apoptosis pathways
  • anti-apoptosis
  • pro-apoptosis
  • prognosis
  • breast cancer

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

23 pages, 4599 KiB  
Article
Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
by Xuemei Xie, Jangsoon Lee, Jon A. Fuson, Huey Liu, Toshiaki Iwase, Kyuson Yun, Cori Margain, Debu Tripathy and Naoto T. Ueno
Biomedicines 2023, 11(3), 735; https://doi.org/10.3390/biomedicines11030735 - 28 Feb 2023
Cited by 1 | Viewed by 2582
Abstract
Background: Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype of breast cancer, and current treatments are only partially effective in disease control. More effective combination approaches are needed to improve the survival of TNBC patients. Eribulin mesylate, a non-taxane microtubule dynamics [...] Read more.
Background: Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype of breast cancer, and current treatments are only partially effective in disease control. More effective combination approaches are needed to improve the survival of TNBC patients. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is approved by the U.S. Food and Drug Administration to treat metastatic breast cancer after at least two previous chemotherapeutic regimens. However, eribulin as a single agent has limited therapeutic efficacy against TNBC. Methods: High-throughput kinome library RNAi screening, Ingenuity Pathway Analysis, and STRING analysis were performed to identify target kinases for combination with eribulin. The identified combinations were validated using in vivo and ex vivo proliferation assays. Results: We identified 135 potential kinase targets whose inhibition enhanced the antiproliferation effect of eribulin in TNBC cells, with the PI3K/Akt/mTOR and the MAPK/JNK pathways emerging as the top candidates. Indeed, copanlisib (pan-class I PI3K inhibitor), everolimus (mTOR inhibitor), trametinib (MEK inhibitor), and JNK-IN-8 (pan-JNK inhibitor) produced strong synergistic antiproliferative effects when combined with eribulin, and the PI3K and mTOR inhibitors had the most potent effects in vitro. Conclusions: Our data suggest a new strategy of combining eribulin with PI3K or mTOR inhibitors to treat TNBC. Full article
(This article belongs to the Special Issue Targeted Therapy for Breast Cancer: Focus on the Apoptosis Pathway)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop